Cantor Fitzgerald Maintains a 'Hold' on Dendreon (DNDN); Understanding Where A Catalyst For Valuation Expansion Will Come From
Tweet Send to a FriendGet Alerts DNDN Hot Sheet
Price: $4.08 -0.49%
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 12 | New: 30
Trade DNDN Now!
Cantor Fitzgerald maintains a 'Hold' on Dendreon (NASDAQ: DNDN) price target lowered from $14 to $12.
Analyst, Mara Goldstein, said, "Provenge's struggle to find a place in the treatment arsenal for prostate cancer may get harder as Zytiga, an anti-androgen, reported that its trial in asymptomatic or mildly symptomatic patients with metastatic castrate resistant prostate cancer (HRPC) who have not received chemotherapy met the criteria for early stopping in a large-scale clinical trial in this setting. This patient population is competitive to Provenge's."
"With shares trading off heavily, the key question is in understanding where a catalyst for valuation expansion will come from. And while we can make the case that the shares are not unreasonably valued at 2.5x cash and 3.3x 2013 revenue, we have less conviction as to where and when such a catalyst will emerge." (Cantor lowers FY13 loss from (1.15) to (1.76) and FY13 revs from $538m to $466.3m)
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.12 yesterday, with a 52 week range of $6.46-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Mara Goldstein, said, "Provenge's struggle to find a place in the treatment arsenal for prostate cancer may get harder as Zytiga, an anti-androgen, reported that its trial in asymptomatic or mildly symptomatic patients with metastatic castrate resistant prostate cancer (HRPC) who have not received chemotherapy met the criteria for early stopping in a large-scale clinical trial in this setting. This patient population is competitive to Provenge's."
"With shares trading off heavily, the key question is in understanding where a catalyst for valuation expansion will come from. And while we can make the case that the shares are not unreasonably valued at 2.5x cash and 3.3x 2013 revenue, we have less conviction as to where and when such a catalyst will emerge." (Cantor lowers FY13 loss from (1.15) to (1.76) and FY13 revs from $538m to $466.3m)
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.12 yesterday, with a 52 week range of $6.46-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: UBS Starts Insmed (INSM) at Buy
- UPDATE: Global Equities Starts Tesla Motors (TSLA) at Overweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
